Dr. Heather J. Male is an Associate Professor of Medicine at the University of Kansas Medical Center.
Dr. Male received her medical degree from the University of Kansas School of Medicine and went on to complete both internal medicine residency and hematology/oncology fellowship through the University of Kansas Medical Center. Her research interests include acute leukemias and hemophagocytic lymphohistiocytosis.
I am an Associate Professor of Medicine in the Department of Internal Medicine, Division of Hematologic Malignancies and Cellular Therapeutics (HMCT) and am principal investigator for multiple acute leukemia clinical trials.
A Rare Cause of Hemophagocytic Lymphohistiocytosis: Fusobacterium Infection-A Case Report and Review of the Literature.
Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission.
Hemophagocytic Lymphohistiocytosis in Pregnancy: A Case Series and Review of the Current Literature.
Histoplasmosis-Associated Hemophagocytic Lymphohistiocytosis: A Review of the Literature.
Is it a Drug or a Bug? A Case of Chemotherapy and Immune Modulators Complicating the Diagnosis of Ehrlichiosis.
A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients with Hematologic Malignancies
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase III, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
A Post-Marketing Observational Study of VYXEOS™ to Assess the Incidence of Infusion-Related Reactions in Adult Patients
Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant